⚠ Paying for Rights It Barely UsesModerate threat

Philip Morris International (PM) — threat to the moat

PMI is amortising $2.8 billion of American IQOS rights over five years while the product is sold in one Texas city.

The IQOS rights are an intangible asset with a clock. PMI amortises the $2.8 billion over five years1, starting when it took full control in May 20242. By the time the amortisation ends in 2029, the rights will have been expensed whether or not IQOS reaches most American smokers.

U.S. IQOS rights timeline20 Oct 2022agreementwith Altria14 Jul 2023$1.8bn paid1 May 2024full rights to PMI27 Mar 2025IQOS 3.0in Austin2029five-yearamortisation endsPMI Form 10-K FY2025; Form 10-Q Q2 2026
The clock started in 2024.

So far the use is small. The limited launch of IQOS 3.0 began in Austin on 27 March 20253, and the ILUMA application submitted on 20 October 2023 and accepted in March 2024 remains pending4.

The cost of delay is that competitors and regulators move in the meantime. Every year IQOS is not on national sale is a year American smokers are being offered other alternatives, including PMI's own ZYN.

The rights also carry a regulatory asset that is already paid for. The FDA renewed the exposure-modification orders for IQOS 2.4 and 3.0 on 17 April 2026, to April 20315, so the device PMI can sell today may make a reduced-exposure claim for another five years. The constraint is distribution and the newer device, not permission for the old one.

The measure that would change this verdict is a national launch date. Without one, a large share of the rights' useful life will have passed before the product reaches the smokers it was bought for.

References
  1. ReportedPMI amortises the $2.8 billion over five years, starting when it took full control in May 2024.
    Philip Morris International Form 10-K for fiscal 2025 - financial statements and notes: income statement, excise, cash flow, debt, acquisitions and impairments. — FY2025 · publ. 6 February 2026 · source ↗
  2. ReportedPMI amortises the $2.8 billion over five years, starting when it took full control in May 2024.
    Philip Morris International Form 10-K for fiscal 2025 - financial statements and notes: income statement, excise, cash flow, debt, acquisitions and impairments. — FY2025 · publ. 6 February 2026 · source ↗
  3. ReportedThe limited launch of IQOS 3.0 began in Austin on 27 March 2025, and the ILUMA application submitted on 20 October 2023 and accepted in March 2024 remains pending.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  4. ReportedThe limited launch of IQOS 3.0 began in Austin on 27 March 2025, and the ILUMA application submitted on 20 October 2023 and accepted in March 2024 remains pending.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
  5. ReportedThe FDA renewed the exposure-modification orders for IQOS 2.4 and 3.0 on 17 April 2026, to April 2031, so the device PMI can sell today may make a reduced-exposure claim for another five years.
    Philip Morris International Form 10-Q for the quarter ended 30 June 2026 - segment results, the balance sheet, FDA authorisations and shares outstanding. — Q2 2026 · publ. 24 July 2026 · source ↗
Sources
Generated September 26, 2026